70岁以上患者接受单倍体移植以移植后环磷酰胺预防GVHD的结局
该研究回顾了93例70岁及以上(中位72岁,范围70-78)接受非清髓预处理和移植后环磷酰胺预防GVHD的单倍体移植患者,2年总生存率53%,无事件生存率43%,180天非复发死亡率14%,2年非复发死亡率27%,2年复发累积发生率30%。180天体重下降可预测后续非复发死亡。
要点
- 70岁以上患者单倍体移植联合PTCy可行且相对安全,2年总生存率53%。
- 非复发死亡率从180天的14%升至2年的27%,部分与年龄相关晚期死亡有关。
核心结论
- 单倍体移植联合PTCy在70岁以上患者中可行且相对安全,早期非复发死亡率较低但2年非复发死亡率继续升高。
研究设计与样本
- 回顾性研究,纳入2009年9月1日至2018年4月1日在约翰霍普金斯医院接受单倍体BMT的93例连续患者,年龄≥70岁(中位72,范围70-78),均接受NMA预处理和PTCy预防GVHD。
主要发现
- 2年总生存率为53%,2年无事件生存率为43%。
- 180天非复发死亡累积发生率为14%,2年非复发死亡累积发生率为27%。
- 2年复发累积发生率为30%。
临床怎么用
- 对于70岁以上血液系统恶性肿瘤患者,单倍体移植联合PTCy可作为可行的治疗选择。
- 移植后180天体重下降可能提示后续非复发死亡风险增加,需关注营养状态和体重变化。
局限性
- 回顾性研究,样本量有限(93例),单中心经验。
- 非复发死亡的预测因素尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematologic malignancies in older people are unlikely to be cured with chemotherapy alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially nonmyeloablative (NMA) conditioning and the use of haploidentical donors, now make this therapy available to older people; however, long-term outcomes and predictors of success are unclear. We reviewed the outcomes of 93 consecutive patients aged 70 and older (median, 72; range, 70-78), who underwent haploidentical BMT at Johns Hopkins Hospital between 1 September 2009 and 1 April 2018. All patients received NMA conditioning and posttransplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis. The 2-year overall survival was 53%, and 2-year event-free survival was 43%. The 180-day cumulative incidence (CuI) of nonrelapse mortality (NRM) was 14%, and the 2-year CuI was 27%. The 2-year CuI of relapse was 30%. Of 78 patients who were alive and had their weight recorded on day 180, weight loss predicted subsequent NRM (subdistribution hazard ratio, 1.0; 95% CI, 1-1.13; P = .048). In conclusion, haploidentical BMT with PTCy is feasible and relatively safe in septuagenarians. Although early, 6-month NRM was relatively low at 14%, but overall NRM continued to climb to 27% at 2 years, at least in part because of late deaths that appeared to be somewhat age related. Further studies to elucidate predictors of NRM are warranted.
引用
- Imus PH, Tsai HL, Luznik L, et al. Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019. PMID: 31492679. doi:10.1182/bloodadvances.2019000155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。